The clinically proven promise of an alopecia drug, without the risks of black box-bearing JAK inhibitors yet with powerful efficacy, led shares of Q32 Bio Inc. (NASDAQ:QTTB) to close July 13 at $21.38, up $10.17, or 90.7%.
Thioredoxin reductase 1 (TXNRD1) is a key component of the thioredoxin antioxidant system that helps maintain cellular redox homeostasis and regulates critical cellular processes such as proliferation, apoptosis and immune responses. A team of researchers at Central South University systematically investigated TXNRD1 expression and function in psoriatic keratinocytes using gene expression datasets, clinical samples and in vitro and in vivo models.
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has announced the teams for the THRIVE (Treating Hereditary Rare diseases with In Vivo prEcision genetic medicines) program. With a commitment of up to $160 million over 5 years, THRIVE aims to accelerate solutions for rare genetic pediatric diseases across multiple technological approaches, clinical trial designs and deployment models.
Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis.
Tvardi Therapeutics Inc. rebounded from a phase II blowup last fall in idiopathic pulmonary fibrosis (IPF) with oral STAT3 inhibitor TTI-101 by showing that a next-gen phosphate prodrug dubbed TTI-109 kept its potency in phase I without gastrointestinal (GI) troubles.
Derm-Biome Pharmaceuticals Inc. has released promising preclinical results for its novel small molecule, DB-006, demonstrating efficacy in treating atopic dermatitis.
Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis.
Avalo Therapeutics Inc. is advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody with potential for hidradenitis suppurativa and additional inflammatory disorders
Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis.
Dermasensor Inc. received CE mark approval for its handheld skin cancer detection device using spectroscopy and AI to test suspicious skin lesions for cancer in real time at the point of care. The device is designed to help qualified healthcare professionals decide whether suspicious skin lesions need further investigation. With skin cancer rates rising, the Dermasensor joins several other AI-based tools entering the European market to help with the analysis of suspicious lesions.
RSS
